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Five New CYLD Mutations in Skin Appendage Tumors
and Evidence that Aspartic Acid 681 in CYLD Is
Essential for Deubiquitinase Activity
Ste´phanie Almeida1, Caroline Maillard1, Peter Itin2, Daniel Hohl1 and Marcel Huber1
Brooke–Spiegler syndrome, familial cylindromatosis, and familial trichoepithelioma are autosomal-dominant
genetic predispositions for benign tumors of skin appendages caused by mutations in the CYLD gene localized
on chromosome 16q12–q13. The encoded protein functions as ubiquitin-specific protease (UBP), which
negatively regulates NF-kB and c-Jun N-terminal kinase (JNK) signaling. We investigated five families affected
with these skin neoplasms and identified four premature stop codons and the novel missense mutation D681G
in a family in which 11 of 12 investigated tumors were trichoepitheliomas. CYLD protein harboring this missense
mutation had a significant reduced ability to inhibit TNF receptor-associated factor (TRAF)2- and TRAF6-
mediated NF-kB activation, tumor necrosis factor-a (TNFa)-induced JNK signaling, and to deubiquitinate TRAF2.
CYLD-D681G was coimmunoprecipitated by TRAF2, but was unable to cleave K63-linked polyubiquitin chains.
Aspartic acid 681 is highly conserved in CYLD homologues and other members of the UBP family, but does not
belong to the Cys and His boxes providing the CYLD catalytic triad (Cys601, His871, and Asp889). As reported
previously, the homologous residue D295 of HAUSP/USP-7 forms a hydrogen bond with the C-terminal end of
ubiquitin and is important for the enzymatic activity. These results underline that D681 in CYLD is required for
cleavage of K63-linked polyubiquitin chains.
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INTRODUCTION
The Brooke–Spiegler syndrome (OMIM 605041), familial
cylindromatosis (OMIM 132700), and familial trichoepithe-
lioma (OMIM 601606) are autosomal-dominant predisposi-
tions to multiple benign adnexal skin tumors (Brooke, 1892;
Spiegler, 1899). The predominating tumors are cylindroma,
trichoepithelioma, and spiradenoma that are mainly loca-
lized on the face and scalp, but less frequently on the neck
and trunk, and which appear generally in early adulthood
(Burrows et al., 1992). These diseases are caused by germline
mutations in a single gene, called CYLD, localized on
chromosome 16q12–q13 (Biggs et al., 1995; Bignell et al.,
2000; Fenske et al., 2000; Takahashi et al., 2000). Loss of
heterozygosity at the same locus was reported in a large
number of these tumors suggesting that CYLD may function
as a tumor suppressor (Biggs et al., 1995, 1996; Takahashi
et al., 2000). Most of the mutations, which are mainly located
at the C-terminal half of the CYLD coding sequence, lead to
the formation of truncated proteins (Bignell et al., 2000, see
also The Human Gene Mutation Database). Until now, only
two missense mutations have been reported in families,
which were mainly affected with trichoepitheliomas (Hu
et al., 2003; Zheng et al., 2004). Three trichoepithelioma
families were mapped to chromosome 9p21 (Harada et al.,
1996) but no gene mutations at this locus have been reported
to date.
Motif analysis revealed that the C-terminal region of CYLD
displayed good sequence similarity to ubiquitin-specific
proteases (UBP, also called USP) (Nijman et al., 2005), a
subfamily of the large group of deubiquitinating enzymes
(Amerik and Hochstrasser, 2004). The N-terminal section has
three CAP-GLY regions, a motif found previously in a number
of microtubule-associated proteins (Bignell et al., 2000).
CYLD interacts with NEMO, TNF receptor-associated
factor (TRAF)-2, and TRAF-interacting protein and negatively
regulates the canonical NF-kB signal transduction pathway
(Brummelkamp et al., 2003; Kovalenko et al., 2003; Regamey
et al., 2003; Trompouki et al., 2003). It does so by acting as
deubiquitinating enzyme, which specifically removes K63-
linked polyubiquitin chains from TRAF2, TRAF6, and NEMO
(Brummelkamp et al., 2003; Kovalenko et al., 2003;
Trompouki et al., 2003). CYLD mRNA is upregulated by
TNFa and bacterium nontypeable Haemophilus influenza,
providing evidence for an inducible autoregulatory feedback
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loop controlling CYLD expression (Jono et al., 2004).
Subsequently, other signaling pathways have been identified
that are regulated by CYLD. c-Jun N-terminal kinase (JNK)
signaling pathway activated by TNFa, anti-CD40 antibody,
IL-1b, and lipopolysaccharide is repressed by CYLD by
reducing the activity of MKK7/JNKK2, which is the mitogen-
activated protein kinase that phosphorylates JNK in response
to these inducers (Reiley et al., 2004). Functional analysis of
thymocytes in CYLD knockout mice revealed that CYLD
functions as a positive regulator of proximal T-cell receptor
signaling by promoting recruitment of active Lck to its
substrate Zap70 (Reiley et al., 2006). Moreover, CYLD
removes polyubiquitin moieties from Lck, counteracting the
activity of c-Cbl ubiquitin (Ub) ligase, which represses Lck
activity. Furthermore, CYLD acts as a negative regulator of
Toll-like receptor 2 signaling by deubiquitinating TRAF6 and
TRAF7 (Yoshida et al., 2005). More recently, it has been
shown that 12-O-tetradecanoylphorbol-13-acetate or UVB
light triggers the translocation of CYLD from the cytoplasm to
the perinuclear region, where it interacts and deubiquitinates
the proto-oncogene Bcl3, a member of the IkB family that can
conjointly with p52 act as transcriptional activator of target
genes such as cyclin D1. Deubiquitination by CYLD prevents
the nuclear translocation of Bcl3 and therefore represses
Bcl3-dependent gene regulation (Massoumi et al., 2006a). In
summary, the deubiquitinase CYLD regulates several signal
transduction pathways in which signal propagation crucially
depends on the polyubiquitination level of key proteins.
We have identified five new CYLD mutations in families
affected with different combinations of skin appendage
tumors. In particular, we report here the missense mutation
D681G found in a family exhibiting predominantly trichoe-
pitheliomas. Biochemical evidence underlines that this
mutation affects the deubiquitinating enzyme activity of
CYLD by strongly reducing its enzymatic activity.
RESULTS
Skin biopsies and blood samples from the index case and at
least one other member from family F1 to F3 (Figure 1a–c)
were collected. Pedigree analysis in these families was
consistent with autosomal-dominant inheritance of the
disease. In addition, specimens of a single member from
two other families (denoted as F4 and F5 in Table 1) were
obtained. However, it is presently unknown whether they
represent familial or sporadic cases, because only one family
member could be examined and no family history was
available. Hematoxylin and eosin stained sections of the
tumors were examined by an experienced dermatopatho-
logist (Table 1). Mainly, cylindromas, trichoepitheliomas, and
a few spiradenomas were found in families F1 and F2. In
contrast, 11 of 12 tumors found at different body sites in three
members of family F3 were classified as trichoepitheliomas,
showing horn cysts with a fully keratinized center surrounded
by basaloid cells (Table 1 and Figure 1e).
Sequence analysis of genomic DNA isolated from blood of
the index cases detected the heterozygous mutations in the
CYLD gene shown in Table 1. In four families, these
mutations were predicted to introduce premature stop
codons. In family F3, whose affected members suffered
primarily from trichoepitheliomas (Table 1), we found an A to
G change at position 2433 (GenBank no. NM_015247) of
human CYLD cDNA mutating aspartic acid 681 to a glycine
residue. We investigated all available family members for the
presence or absence of these mutations. In each family, the
genotype correlated well with the occurrence of tumors
except in family F1 in which individual IV-1 (Figure 1a,
asterisk) was a carrier for the mutation but did not yet show
any skin lesions at the age of 23.
Aspartic acid at position 681 of human CYLD does not
belong to the Cys (amino acids 590–610) or to the His box
(amino acids 870–890), which are two well-conserved motifs
within UBPs (Nijman et al., 2005). Both of these regions were
proposed to be essential for deubiquitinase activity (Brum-
melkamp et al., 2003; Kovalenko et al., 2003; Trompouki
et al., 2003; Amerik and Hochstrasser, 2004). The region
surrounding D681 of human CYLD is not very well conserved
between members of the UBP subfamily and CYLD (Figure
2b). However, it is highly conserved in vertebrate and
invertebrate CYLD homologues (Figure 2a), suggesting that
it might have a crucial function. To investigate the biological
consequences of the D681G mutation on CYLD function, we
assessed the regulation of CYLD-dependent signaling path-
ways by CYLD-D681G in comparison with wild-type (WT)
protein or CYLD-C601A (active-site mutant).
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Figure 1. Genetic and clinical data of families affected with skin appendage
tumors. Pedigrees of (a) family F1, (b) family F2, and (c) family F3 which
are shown in Table 1. Arrows denote the index case in each family.
M and N mark the presence or absence of the heterozygous mutations in
the germline, respectively. Black symbols identify individuals with tumors.
(d) Photograph of the index case from family F3 showing trichoepitheliomas.
(e) Hematoxylin and eosin stained section of tumor isolated from the
shoulder of the F3 index case. Bar¼50 mm.
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In contrast to the WT protein, both mutants did not reduce
NF-kB activity induced by TRAF2 (Figure 3a) and TRAF6
(Figure 3b). These findings were not caused by differences in
protein expression (Figure 3, lower panels). To address the
question whether CYLD-D681G can downregulate the JNK
pathway activated by TNFa (20ng/ml for 15minutes) (Reiley
et al., 2004), a nonradioactive glutathione S-transferase-c-jun
pull-down kinase assay was performed with cell extracts from
293T cells expressing normal and mutant CYLD proteins.
Although CYLD-D681G and CYLD-C601A were present at
levels similar to WT CYLD (Figure 4, lower panel), higher
levels of phosphorylated c-Jun protein were found in the
presence of the mutants (Figure 4, upper panel), indicating that
they were unable to inhibit TNFa-mediated activation of JNK.
Furthermore, we tested how the D681G mutation
affected the deubiquitinase function of CYLD. 293T cells
were co-transfected with vectors expressing myc-TRAF2,
hemagglutinin A (HA)-Ub, and the different Flag-CYLD
proteins. The ubiquitination level of immunoprecipitated
TRAF2 was assessed by anti-HA immunoblot analysis.
Overexpression of WT CYLD caused a substantial reduction
in TRAF2 ubiquitination (Figure 5a, upper panel) (Brummelk-
amp et al., 2003; Kovalenko et al., 2003; Trompouki et al.,
2003; Reiley et al., 2005), whereas the ubiquitination level of
TRAF2 after co-transfection with CYLD mutants was similar
to the control without CYLD (Figure 5a, upper panel). This
shows that D681 of CYLD is required for TRAF2 deubiqui-
tination. No significant differences in the expression levels of
TRAF2 and CYLD proteins were observed (Figure 5a, lower
panels). The WT and the two mutant CYLD proteins were
coimmunoprecipitated by TRAF2 (Figure 5b), showing that
reduced deubiquitination of TRAF2 by CYLD-D681G is not
caused by diminished binding to TRAF2. Although WT
protein cleaved in vitro Lys63-linked polyubiquitin chains
partially to monomeric Ub (see right lane in Figure 5c, upper
panel), cleavage by CYLD mutants was strongly reduced
(Figure 5c), indicating that D681 in human CYLD is important
for Lys63-linked polyubiquitin chain cleavage.
DISCUSSION
It is now well established that CYLD mutations cause familial
cylindroma, familial trichoepithelioma, and Brooke–Spiegler
syndrome, suggesting that these diseases represent phenoty-
pic variations of the same disease entity. We have identified
five new mutations in the CYLD gene (four premature stop
codons and one missense mutation) in families suffering from
these skin appendage neoplasms. In particular, we examined
the functional consequences of the missense mutation
Table 1. CYLD mutations, tumor types, and body locations in five families
Family Exon Germline mutation Codon1 Individual2 Sex Age at diagnosis Age3 Tumor4 Body site
F1 15 DelT2472 L694X III-2 F 24 49 TE Buttock
SP Back
CYL Scalp
F2 19 G2937A W849X I-1 M 35 35 CYL Scalp
57 CYL Scalp
II-3 F 38 38 TE Forehead
III-1 F 5 10 CYL Scalp
TE Nose
III-2 M 8 8 TE Forehead
F3 15 A2433G D681G II-3 M N/A 55 TE Buttock
56 TE(2) Ear
62 SP N/A
63 TE Occiput
TE Neck
TE Trunk
III-1 M 18 18 TE Buttock
III-2 M 22 22 TE(2) Back
TE Forehead
TE Occiput
F4 10 C1518T N403X F N/A 67 CYL Scalp
F5 9 G1526T E379X M 35 76 CYL Scalp
CYL, cylindroma; F, female; M, male; N/A, not available; SP, spiradenoma; TE, trichoepithelioma.
1Amino-acid mutation; X denotes stop codon.
2Individuals according to pedigrees shown in Figure 1.
3Age at which tumor was removed.
4(2), number of isolated tumors from the same body site.
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D681G discovered in a family affected almost exclusively
with multiple trichoepitheliomas. Similarly to active-site
C601 CYLD mutants (Trompouki et al., 2003; this work),
CYLD-D681G was unable to inhibit TRAF2- or TRAF6-
mediated activation of NF-kB and TNFa activation of JNK,
and to deubiquitinate TRAF2. The latter was not caused by
reduced binding to TRAF2, as shown by coimmunoprecipita-
tion but by a strongly reduced ability to cleave K63-linked
polyubiquitin chains. This is in agreement with results
mapping the TRAF2-binding site of CYLD to amino acids
453–457 (Kovalenko et al., 2003).
CYLD belongs to the UBP family, which is mainly
involved in removing Ub moieties from proteins larger than
20–30 amino acids (Amerik and Hochstrasser, 2004; Nijman
et al., 2005). Mutagenesis experiments identified a conserved
triad Cys-Asp/Asn-His that has a critical role in catalysis
(Huang et al., 1995; Gilchrist and Baker, 2000; Baek et al.,
2001; Amerik and Hochstrasser, 2004). Based on these
findings and sequence alignments with UBP proteins, the
CYLD catalytic triad was putatively assigned to Cys601,
His871, and Asp889 (Kovalenko et al., 2003). Although the
region around aspartic acid 681 does not belong to the
catalytic triad, the functional importance of this region is
emphasized by the high conservation in CYLD homologues
(Figure 2a) and, albeit to a lesser degree, in other members of
the UBP family (Figure 2b). Recent structural and molecular
data of the UBP HAUSP/USP-7 showed that Asp295, which is
homologous to human CYLD Asp681 (Figure 2b), hydrogen
bonds to the amide of Leu73 from Ub. In addition, mutating
D295 disabled HAUSP/USP-7 to cleave Lys48-linked diubi-
quitin (Hu et al., 2002). Similarly, our data indicate that
alteration of D681 abolishes the deubiquitinating activity of
CYLD by inhibiting the K63-linked polyubiquitin cleavage
ability. Whether this is caused by reduced binding of CYLD-
D681G to polyubiquitin or by affecting the catalytic
mechanism remains to be determined.
Analyses of germline CYLD mutations in familial cylin-
dromatosis, familial trichoepithelioma, and Brooke–Spiegler
syndrome revealed the preponderance of premature stop
codon mutations in all three clinical forms. The two reported
CYLD missense mutations, E747G and D941V, were detected
in families affected primarily with trichoepithelioma (Hu
et al., 2003; Zheng et al., 2004). Both residues are highly
conserved in CYLD homologues, but are not conserved in
other members of the UBP family and are localized to regions
outside of the active-site cysteine and the His box. The D941
residue is situated two amino acids before two conserved
tyrosine residues (YXXXY). The HAUSP/USP-7 crystal struc-
ture identified the first of these tyrosines to make van der
Waals contacts with the C-terminal end of bound Ub (Hu
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Figure 3. Regulation of TRAF2- and TRAF6-mediated NF-jB activation by
WT and mutant CYLD proteins. NF-kB reporter assays in 293T cells
co-transfected with WT or mutant (D681G and C601A) Flag-CYLD and
either (a) Flag-TRAF2 or (b) Flag-TRAF6. Luciferase activities were measured
24hours after transfection. The presence of proteins in cell extracts was
analyzed by immunoblots using anti-Flag antibody (lower panels). Results are
reported as mean7SEM from duplicates of one representative experiment.
These assays were carried out five (TRAF2) or three (TRAF6) times with
essentially the same results.
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et al., 2002). The functional importance of this stretch is
further underlined by the finding of a premature stop codon at
R936 in a cylindroma family (Bignell et al., 2000). As the
amino acid E747 and its neighboring sequences in CYLD are
not conserved in other UBPs, it is difficult to predict the
functional role of this residue at the moment. Interestingly,
we report now the third missense mutation in the CYLD gene,
again in a family predominantly affected with trichoepithe-
liomas (F3 in Table 1). Whether there is indeed an association
between CYLD missense mutations and trichoepithelioma
formation awaits further molecular analysis. Previous work
provided no evidence for a genotype/phenotype correlation
(Bowen et al., 2005).
Cylindroma and trichoepithelioma are thought to originate
from hair follicle cells (Massoumi et al., 2006b). In CYLD
knockout mice, tumors are only formed after treating animals
with a two-stage carcinogenesis protocol, suggesting that
mutations in other genes are required for tumor development
(Massoumi et al., 2006a). In humans, these tumors develop
mainly on sun-exposed body sites suggesting that additional
UV-induced mutations may play a crucial role in their
formation. The level of signaling molecules regulating
follicular-sebaceous-apocrine differentiation of committed
progenitor cells will influence the decision regarding which
tumor type is formed. Additional mutations may alter these
levels changing the differentiation phenotype of the tumor, as
shown recently for LEF1 inactivating mutations that lead to
the expression of sebocyte differentiation markers and the
formation of sebaceous tumors (Takeda et al., 2006).
Furthermore, differences in the biological activity of modifier
genes caused by genetic or epigenetic alterations may
determine the outcome of a cancer-promoting insult. For
example, polymorphic variants of the Patched gene decide
whether K5Hras transgenic mice develop early-onset squa-
mous cell carcinomas (Wakabayashi et al., 2007). In
summary, these molecular mechanisms may explain the
diversity of tumor types which are initiated by mutations in
the same gene.
MATERIALS AND METHODS
Clinical samples
Biopsies and blood samples were obtained from the patients with
their written informed consent. The study, approved by the Medical
Ethical Committee of the Faculty of Biology and Medicine at the
University of Lausanne (Lausanne, Switzerland), was conducted
according to the Declaration of Helsinki Principles. Tumors were
classified by an approved dermatopathologist.
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Figure 5. Deubiquitination of TRAF2 and in vitro cleavage of K63-linked
polyubiquitin by CYLD. (a) 293T cells were co-transfected with mycTRAF2,
HA-Ub and WT or mutant Flag-CYLD. The level of ubiquitinated TRAF2 was
examined by anti-myc immunoprecipitations (IP) and immunoblotting (IB)
with anti-HA antibody (upper panel). The amount of immunoprecipitated
TRAF2, and of CYLD proteins in total cell extracts was detected using
anti-myc antibody (middle panel) and anti-Flag antibody (lower panel),
respectively. (b) 293T cells were co-transfected with mycTRAF2 and WT or
mutant Flag-CYLD. After immunoprecipitation with anti-myc antibody, the
amount of coimmunoprecipitated CYLD was examined with anti-Flag
antibody (upper panel). The middle and lower panels depict the quantities of
immunoprecipitated TRAF2 and of CYLD in total cell extracts, respectively.
(c) A 2mg portion of K63-linked polyubiquitin (poly-Ub2–7) chains was
incubated with WT or mutant Flag-CYLD protein immunopurified from
transfected 293T cells. Cleaved proteins were detected by silver staining after
electrophoresis in a 4–20% gradient SDS-PAGE gel (upper panel). Arrows
mark the positions of CYLD proteins and the polyubiquitin chains. The
amount of immunopurified CYLD protein was estimated by immunoblotting
using anti-Flag antibody (lower panel).
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DNA sequence analysis
DNA was extracted from blood using the Nucleon BACC1 kit (GE
Healthcare, Otelfingen, Switzerland). Sequence analysis of exons
9–20 of the CYLD gene were carried out as described (Bignell et al.,
2000).
Plasmids
The pNF-kB-luc and pRL-TK vectors were purchased from Stratagene
(Amsterdam, The Netherlands) and Promega (Wallisellen, Switzer-
land). To generate the pCYLD2 vector, N-terminal Flag-tagged
human CYLD cDNA from the pCYLD1 vector (Regamey et al., 2003)
was cloned into the pCI expression vector (Promega, Wallisellen,
Switzerland). Point mutations were introduced into pCYLD2 using
the QuikChangeII kit (Stratagene) to generate pCYLD2-D681G and
pCYLD2-C601A. All constructs were verified by sequencing
(Synergene, Schlieren, Switzerland). Vectors for expressing HA-Ub,
Flag-TRAF2, and Flag-TRAF6 were provided by Drs. G. Courtois and
P. Schneider.
Cell culture and NF-jB reporter assays
293T cells were cultured as described (Regamey et al., 2003). Cells
in 24-well plates (50,000 cells/well) were transfected 24 hours after
seeding with 0.1 mg of the indicated expression plasmids, 0.2 mg of
pNF-kB-luc, and 0.01 mg of pRL-TK using Lipofectamine 2000
reagent (Invitrogen, Basel, Switzerland). After 24 hours, luciferase
activities were measured using the Dual-Luciferase-Reporter Assay
System (Promega). Results are reported as mean7SEM from
duplicates of one representative experiment. These assays were
carried out three (TRAF6) or five (TRAF2) times with essentially the
same results as shown.
JNK assay
The day before transfection, 293T cells were seeded in six-well
plates (8 105 cells/well). Cells were transfected with 1.9 mg
plasmids expressing either WT or mutant CYLD proteins
using the standard calcium phosphate method (van der Eb and
Graham, 1980). After 24 hours, cells were treated with 20 ng/ml of
human TNFa (R&D Systems, Abingdon, UK) for 15minutes.
Protein extraction, kinase reaction, and phospho c-Jun
detection were carried out according to the SAPK/JNK Assay
Kit Manual (Cell Signaling Technology, Allschwil, Switzerland).
The experiment was repeated entirely twice with similar results
obtained.
TRAF2 deubiquitination assay and coimmunoprecipitation
293T cells were transfected as described above with 0.5 mg of
expression plasmids for HA-Ub, myc-TRAF2, and 0.7 mg of plasmids
expressing WT or mutant Flag-CYLD proteins. Forty-eight hours after
transfection, cells were lysed in 0.5% SDS/phosphate-buffered
saline, heated for 2minutes at 851C, and centrifuged. Supernatants
were diluted 1:10 with RIPA buffer and used for immunoprecipita-
tions (Regamey et al., 2003) with mouse anti-myc antibody (9B11;
Cell Signaling Technology). Immunoprecipitates were analyzed by
immunoblot using rabbit anti-HA antibody (Y-11; Santa Cruz
Biotechnology, Nunningen, Switzerland) and rabbit anti-myc anti-
body (A-14; Santa Cruz Biotechnology). CYLD proteins were
detected in total cell extracts using mouse anti-Flag M2 antibody
(F1804; Sigma, Buchs, Switzerland). Identical results were observed
in three independent assays. TRAF2/CYLD coimmunoprecipitations
were carried out as described (Regamey et al., 2003) using the
aforementioned antibodies.
Cleavage of K63-linked polyubiquitin chains
Flag-CYLD proteins were purified from transfected 293T cells by
Flag immunoprecipitation and protein elution using Flag peptide
(500mg/ml) (Trompouki et al., 2003). A 10 ml portion of immuno-
precipitated proteins was incubated with 2mg of K63-linked
polyubiquitin chains (mixture of 2–7 Ub units; BostonBiochem,
Lausen, Switzerland) at 371C for 2 hours. After electrophoresis
through a 4–20% linear gradient SDS-PAGE gel, samples were
analyzed by silver staining or immunoblotting using anti-Flag M2
antibody.
Sequence comparison
Protein sequence alignments were calculated using the T-Coffee
analysis program (Notredame et al., 2000).
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